European Journal of Molecular & Clinical Medicine

Abstract

Introduction: Cutaneous warts are treated primarily with destructive methods such as topical keratolytics, electrocoagulation, cryotherapy or laser therapy or electrocautery. These modalities of treatment are time-consuming and may be associated with scarring in multiple warts. Immunotherapy is emerging as a new modality of treatment which acts on enhancing cell-mediated immunity against human papillomavirus for clearance of both treated and distant warts.
Aim and Objective of the study: The aim of our study is to evaluate the safety and efficacy of intralesional vitamin D3 in the treatment of cutaneous warts.
Materials and Methods: Larger warts were considered for the injection. A maximum of 2 warts were treated at each session. The injections were repeated at 2 weekly intervals for a maximum of four injections. If complete clearance was achieved before four injections, the treatment was stopped, and patient was followed up for recurrence. Patients were evaluated for treatment efficacy and adverse reactions every 2 weeks for first 2 months and monthly thereafter to record for any recurrence for 6 months.
Results: In the present study, 27 patients had palmoplantar warts, out of which 19 (70%) had complete clearance, 6 (22.2%) had moderate clearance and 2 (7.4%) patients had mild clearance. 22 patients had verruca vulgaris, out of which 15 (68.18) had complete clearance, 5 (22.7%) had moderate clearance and 2 (9.09%) had mild clearance. Only 2 patients had filiform wart, out of which 1 (50%) had moderate clearance and 1 (50%) had mild clearance. 
Discussion and conclusion: Intralesional Vitamin D3 injection is a novel approach for the treatment of warts. It is inexpensive, safe and special value to treat multiple warts in developing countries. Our study showed good response to the treatment in subjects suffering from cutaneous warts.